Accelerate early-phase vaccine development with a proven approach to reduce serum use and enhance viral vector yields. Discover how animal-origin-free supplements can improve performance, consistency, and scalability in vaccine development.
March 23, 2026
Sponsored by
As vaccine developers transition away from animal serum, identifying reliable, scalable alternatives is critical for early-phase programs. This application note highlights two case studies demonstrating how animal origin–free supplements support adherent Vero and suspension HEK293 cell growth while enhancing viral vector production.
Under reduced-serum conditions, optimized blends increased VSV titers, and targeted supplementation improved adenovirus yields by over 50% compared to controls.
Backed by rigorous quality control and a data-driven Key Driver Identification (KDI) approach, these solutions help reduce variability, improve consistency, and accelerate progress from preclinical development through manufacturing.
